arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Avalo Therapeutics, Inc.

AVTX
$18.34 ▼ -0.42 (-2.24%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
14 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Avalo Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $245.8M
Dividend Yield
Revenue Growth -86.6%
Op. Margin None
ROIC -88.0%
FCF / Share $-3.84
Trailing P/E
Price / Book 4.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$59.00K
↓ -86.6%
Net Income Profit after all expenses
$-78.26M
↓ -122.8%
Operating Margin Operating profit as % of sales
-207.4%
↑ +13.2%
FCF / Share Free cash flow per share
$-3.84
↑ +65.4%
Long-Term Debt Long-term obligations
$14.33M
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Cash Quality
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 50 quarters